Ono Pharmaceutical’s Q1 FY2027 financial results show net sales of 116.2 billion yen (YoY +0.4%) and net income of 17,631 million yen (YoY +1.0%). Overseas sales are approximately 12.9 billion yen, domestic sales about 87.8 billion yen. Key products include Opdivo and strong performances in overseas markets. The outlook predicts sustained growth.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4528","jir_company_name":"Ono Pharmaceutical Co., Ltd.","jir_importance":"\u2605\u2605\u2605\u2605\u2605","jir_publication_date":"2026-07-31","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/07\/4528-20260731-01.pdf","jir_short_summary":"Ono Pharmaceutical's Q1 FY2027 financial results show net sales of 116.2 billion yen (YoY +0.4%) and net income of 17,631 million yen (YoY +1.0%). Overseas sales are approximately 12.9 billion yen, domestic sales about 87.8 billion yen. Key products include Opdivo and strong performances in overseas markets. The outlook predicts sustained growth.","jir_summary":"### Financial Details and Future Outlook\nSales remain steady, with slight increases in net income. Growth in overseas sales continues to support overall performance, with further overseas expansion expected to be key for revenue growth. R&D expenses are increasing but are positioned as long-term growth investments. Attention is paid to exchange rate effects and new drug launch schedules to build a stable earnings base.","jir_financial_highlights":"Net Sales: 116.2 billion yen (YoY +0.4%)\nNet Income: 17,631 million yen (YoY +1.0%)\nOverseas Sales: about 12.9 billion yen (YoY +\u7d042.9 billion yen)","jir_category":"","jir_hashtags":"#OnoPharmaceutical, #IRFinancialResults, #JapanStocks","jir_key_figures":"Net Sales: 116.2 billion yen (YoY +0.4%)\nNet Income: 17,631 million yen (YoY +1.0%)\nOverseas Sales: about 12.9 billion yen (YoY +\u7d042.9 billion yen)","jir_meta_title":"\u3010Ono Pharmaceutical\u3011FY2027 Q1 Financial Results\uff5cNet Sales 116.2 billion yen (+0.4%)","jir_meta_description":"Ono Pharmaceutical's FY2027 Q1 financial results show net sales of 116.2 billion yen (YoY +0.4%) and net income of 17,631 million yen ( +1.0%). The report details overseas expansion and new drug strategies.","jir_og_title":"\u3010Ono Pharmaceutical\u3011FY2027 Q1 Financial Results\uff5cNet Sales 116.2 billion yen (+0.4%)","jir_og_description":"Ono Pharmaceutical's FY2027 Q1 financial results maintain steady sales and profits. The focus is on overseas expansion and new drug development to achieve long-term growth.","jir_og_image_url":"\/assets\/og\/company-financial_summary.jpg","jir_chart_data_collection":"[{\"jir_chart_id\": \"revenue_trend\", \"jir_chart_type\": \"line\", \"jir_chart_title\": \"Net Sales Trend\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"line\\\",\\\"data\\\":{\\\"labels\\\":[\\\"2026 Q1\\\",\\\"2026 Q2\\\",\\\"2026 Q3\\\",\\\"2026 Q4\\\",\\\"2027 Q1\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Net Sales\\\",\\\"data\\\":[275,290,300,297,291],\\\"borderColor\\\":\\\"#36A2EB\\\",\\\"fill\\\":false}]}}\"}, {\"jir_chart_id\": \"profit_trend\", \"jir_chart_type\": \"line\", \"jir_chart_title\": \"Net Income Trend\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"line\\\",\\\"data\\\":{\\\"labels\\\":[\\\"2026 Q1\\\",\\\"2026 Q2\\\",\\\"2026 Q3\\\",\\\"2026 Q4\\\",\\\"2027 Q1\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Net Income\\\",\\\"data\\\":[176,177,176,177,176],\\\"borderColor\\\":\\\"#4BC0C0\\\",\\\"fill\\\":false}]}}\"}, {\"jir_chart_id\": \"overseas_sales\", \"jir_chart_type\": \"bar\", \"jir_chart_title\": \"Overseas Sales\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"bar\\\",\\\"data\\\":{\\\"labels\\\":[\\\"2026 Q1\\\",\\\"2026 Q2\\\",\\\"2026 Q3\\\",\\\"2026 Q4\\\",\\\"2027 Q1\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Overseas Sales\\\",\\\"data\\\":[25,27,28,29,29],\\\"backgroundColor\\\":\\\"#FF6384\\\"}]}}\"}]","ir_related_company":7530,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"financial_summary","footnotes":""},"sector":[],"importance":[],"class_list":["post-91153","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n